

Automated AST – a curse?

Gunnar Kahlmeter

Clinical Microbiology

Växjö and Karlskrona

Sweden

ESCMID Online © by author

Is it a curse? Of course not!! Vincent is right! It is a blessing!

That is..... When the machine does what we want it to do, automatically, immediately, with the right output, is always updated with the latest changes in breakpoints or "rules", new antibiotics, with all species and drugs available, with no delays in development and

...then Vincent is right!

Interactive session

- Everyone in the audience with an automated AST device – raise a hand!
- Who has a Microscan – raise a hand!
- Who has a Phoenix – raise a hand!
- Who has a Vitek2 – raise a hand!
- Who has another automated AST device?

Now use the blue voting card!

All who are happy with the flexibility of their
automatic AST device

raise the **blue** card!


ESCMID Online © 2014

Methods for antimicrobial susceptibility testing


- Broth dilution
- Broth microdilution (BMD)
- Agar dilution
- Gradient tests
- Disk (or tablet) diffusion

ESCMID Online © 2014

Broth dilution




Broth microdilution



ESCMID

Online Lecture Library
© by author

Agar dilution



Disk diffusion AST

Semiautomated



Fully automated?
Future perspectives!

Automated (semi-) AST systems

- **MIC-based**

- Broth microdilution (cards or microtiter trays)

- Phoenix (BD)

- Microscan (Siemens)

- Sensititre (Trek, Thermo Scientific)

- Growth curve algorithm

- Vitek2 (bioMerieux)

- **Disk Diffusion**

- Biomic (Giles Scientific)

- Sirscan (Oriana)

- Osiris (Biorad)

Limited concentrations series

- Microscan
- Phoenix
- Vitek2

Flexible concentration series

- Sensititre

ESCMID Online © by author

MIC based automatic systems



AST and MIC devices

- **AST devices**

- Test output: category S, I, R (IE or "-")
- Microscan, Phoenix, Vitek2
- Dependent on match between limited concentration series, breakpoints and expert rules
- Assessed by **categorical** agreement

- **MIC determination devices**

- Test output: MIC (mg/L)
- Sensititre (dependent on correct dilution series)
- Gradient tests (Etest, M.I.C.E., MIC Test Strip) depend on correct calibration to broth microdilution
- Independent of breakpoints and expert rules
- Assessed by **essential** agreement

Disadvantages of most of current automation in antimicrobial susceptibility testing

- Limited capacity
- Black box technique
- Much of system outside user control
- “Rapid” results are not more rapid than a gradient test or a disk diffusion

**Do not fully meet EUCAST standards..
and are slow in getting there**

- Does not cover all tests – require supplementary systems
- User variation in setup
- “Expert rules systems” require certain antibiotics present on card.
- Some resistance mechanisms not reliably detected
- Commercial decisions affect presentation
- More expensive on consumables! Savings on labour?
- Lab tied to one system for a protracted period (through capital investment or lease contract)

Problems with machines

What they do, they do well.

The problems are with what they do not do!

- Missing species
- Missing drugs
 - New drugs take time to develop
 - New drugs take time to approve
 - Existing drugs not always suitable (pivmecillinam, piperacillin/tazobactam)
 - Some drugs necessary to make "expert rules work"
- Incomplete MICs (truncated dilution series)
 - too many \leq and \geq
- EUCAST
 - terminology out of whack ($R>$ and $R\geq$)
 - "IC" not handled (report value without interpretation)
 - "–" not handled (intrinsic resistance: report "R" or not at all)
- Approval process focused on CA instead of EA – next slide

Missing species

Phoenix

H. influenzae
M. catarrhalis
N. gonorrhoeae
N. meningitidis
Gram-positive anaerobes
Gram-negative anaerobes

MicroScan

Streptococcus A, C and G
S. pneumoniae
S. viridans (test available only for *S. bovis*)
H. influenzae
M. catarrhalis
N. gonorrhoeae
N. meningitidis
Gram-positive anaerobes
Gram-negative anaerobes

Vitek2

H. influenzae
N. gonorrhoeae
Gram-positive anaerobes

M. catarrhalis
N. meningitidis
Gram-negative anaerobes

Problems with machines

What they do, they do well.

The problems are with what they do not do!

- Missing species
- Missing drugs
 - New drugs take time to develop
 - New drugs take time to approve
 - Existing drugs not always suitable (pivmecillinam, piperacillin/tazobactam)
 - Some drugs necessary to make "expert rules work"
- Incomplete MICs (truncated dilution series)
 - too many \leq and \geq
- EUCAST
 - terminology out of whack ($R>$ and $R\geq$)
 - "IC" not handled (report value without interpretation)
 - "–" not handled (intrinsic resistance: report "R" or not at all)
- Approval process focused on CA instead of EA – next slide

Missing drugs

Phoenix

Breakpoints Not Available	Antibiotics Not Available
Rifampicin (Staphylococci) Trimethoprim (Enterococci) Cotrimoxazole (Enterococci)	None

MicroScan

Breakpoints Not Available	Antibiotics Not Available
Trimethoprim Chloramphenicol Fusidic acid Rifampicin	Tigecycline/Gram-positive organisms Roxithromycin Telithromycin Doxycycline

Vitek2

Breakpoints Not Available	Antibiotics Not Available
Ampicillin-sulbactam Rifampicin Netilmicin (Staphylococci) Trimethoprim (Enterococci) Trimethoprim-sulfa (Enterococci) Gentamicin (Enterococci) Ofloxacin (Pneumococci)	Cefadroxil Ceftibuten Azithromycin Roxithromycin Ampicillin (Pneumococci) Cefepime (Pneumococci) Cefpodoxime (Pneumococci) Cefuroxime (Pneumococci) Teicoplanin (Pneumococci) Doxycycline (Pneumococci) Minocycline (Pneumococci)

Problems with machines

What they do, they do well.

The problems are with what they do not do!

- Missing species
- Missing drugs
 - New drugs take time to develop
 - New drugs take time to approve
 - No room on cards
 - Some drugs necessary to make "expert rules work"
- Incomplete MICs (truncated dilution series)
 - too many \leq and \geq
- EUCAST
 - terminology out of whack ($R>$ and $R\geq$)
 - "I" not handled (report value without interpretation)
 - "–" not handled (intrinsic resistance: report "R" or not at all)
- Approval process focused on CA instead of EA – next slide

Problems with machines


What they do, they do well.

The problems are with what they do not do!

- Missing species
- Missing drugs
 - New drugs take time to develop
 - New drugs take time to approve
 - No room on cards
 - Some drugs necessary to make "expert rules work"
- Incomplete MICs (truncated dilution series)
 - too many \leq and \geq
- EUCAST
 - terminology out of whack ($R>$ and $R\geq$)
 - "I" not handled (report value without interpretation)
 - "-" not handled (intrinsic resistance: report "R" or not at all)
- Approval process focused on CA instead of EA – next slide

Ciprofloxacin / Escherichia coli
EUCAST MIC Distribution - Reference Database 2012-03-27

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance




The dilemma of manufacturers:
How many concentrations to include?
Covering which interval? Up? Down?
Different intervals for CLSI and EUCAST?
How do I plan for the future?

MIC Epidemiological cut-off: WT ≤ 0.064 mg/L

17903 observations (83 data sources)
Clinical breakpoints: S ≤ 0.5 mg/L, R > 1 mg/L

Ciprofloxacin / Escherichia coli EUCAST MIC Distribution - Reference Database 2012-03-27

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance




MIC Epidemiological cut-off: WT ≤ 0.064 mg/L

17903 observations (83 data sources)
Clinical breakpoints: S ≤ 0.5 mg/L, R > 1 mg/L

Ciprofloxacin / Escherichia coli EUCAST MIC Distribution - Reference Database 2012-03-27

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



MIC Epidemiological cut-off: WT ≤ 0.064 mg/L

17903 observations (83 data sources)
Clinical breakpoints: S ≤ 0.5 mg/L, R > 1 mg/L

Problems with machines

What they do, they do well.

The problems are with what they do not do!

- Missing species
- Missing drugs
 - New drugs take time to develop
 - New drugs take time to approve
 - No room on cards
 - Some drugs necessary to make "expert rules work"
- Incomplete MICs (truncated dilution series)
 - too many \leq and \geq
- **EUCAST**
 - terminology out of whack ($R>$ and $R\geq$)
 - "IE" not handled (report value without interpretation)
 - "–" not handled (intrinsic resistance: report "R" or not at all)
- Approval process focused on CA instead of EA.

EUCAST terminology lacking

Phoenix

S ≤	R >	-	IE
Yes	No (R ≥)	Yes	Yes
Yes	Yes (converted to R >)	Yes*	Yes*

MicroScan

S ≤	R >	-	IE
Yes	Yes	No	No
Yes	Yes	Most "-" do not have interpretations reported	No

Vitek2

S ≤	R >	-	IE
Yes	No	No*	No**
Yes	No	No*	No**
		* not reported or reported R	** not reported

Problems with machines

What they do, they do well.

The problems are with what they do not do!

- Missing species
- Missing drugs
 - New drugs take time to develop
 - New drugs take time to approve
 - No room on cards
 - Some drugs necessary to make "expert rules work"
- Incomplete MICs (truncated dilution series)
 - too many \leq and \geq
- **EUCAST**
 - terminology out of whack ($R>$ and $R\geq$)
 - "IE" not handled (report value without interpretation)
 - "–" not handled (intrinsic resistance: report "R" or not at all)
- Approval process focused on CA instead of EA.

Successful CA depends on...

- Collection of isolates
 - Isolates with only low and high MICs are easier to deal with
- Some breakpoints more difficult to deal with than others
 - Breakpoints which divide wild type distributions
 - Narrow or no I-category

ESCMID Online © 2012 by ESCMID

Cipro 5 μ g Salmonella


Breakpoint for
susceptibility in M100



Zone diam	CIP MIC								Total
	0,02	0,03	0,06	0,12	0,25	0,5	1	2	
21							2		2
22						5	6		11
23						9	13	2	24
24						11	17	1	29
25						19	17	1	37
26					1	12	6		19
27					4	3	2		9
28					14	6	1		21
29				2	16	10			28
30				3	10	1			14
31		3		2	3				8
32		8		1	2				11
33		21	2						23
34	1	35	4		2				42
35	6	25	2						33
36	4	10							14
37	7	6							13
38	6	4							10
39	1								1
40	3								3
Total	28	112	8	8	52	76	64	4	352

Erythromycin 15 µg vs. MIC, *Campylobacter jejuni* 30 clinical isolates tested in duplicate

ECOFF: WT ≤ 4 mg/L



Future phenotypic AST (6 – 8 - 16h)

- Automated **MIC testing**
 - Fully automatic? Provide inoculum?
 - “Full” MIC-ranges (see next slide)!
 - 96 wells? 196 wells? 1196 wells? etc
 - Incubation and variable reading after 6, 8, 10 etc ...20h depending on **species** and **antibiotic**.
 - 6 – 8 h (!?) – new techniques for measuring growth may reduce time.
 - Software downloading breakpoints and ECOFFs from internet.
 - **Output**: MIC + Clinical S, I or R + WT or NWT

Cefotaxime and enterobacteriaceae

Breakpoints: S≤1 / R>2 mg/L

ECOFFs 0.12 – 1 mg/L

	0.002	0.004	0.008	0.016	0.032	0.064	0.125	0.25	0.5	1	2	4	8	16	32	64	128	256	512	S≤	R>	ECOFFs
Citrobacter freundii	0	0	0	0	1	3	42	5	5	2	3	4	3	18	18	5	1	0	0	1.0	2.0	0.5
Citrobacter spp	0	0	0	0	17	35	19	11	10	9	2	4	3	4	4	3	0	0	0	1.0	2.0	0.5
Enterobacter aerogenes	0	0	0	0	7	28	33	9	3	3	4	2	8	15	8	9	6	11	0	1.0	2.0	0.5
Enterobacter cloacae	0	0	1	6	19	64	213	189	129	44	28	19	35	53	90	59	56	58	12	1.0	2.0	0.5
Enterobacter spp	0	0	0	1	19	47	79	45	29	22	7	10	4	20	11	4	0	5	0	1.0	2.0	0.5
Escherichia coli	0	5	40	282	1656	4953	2591	485	94	100	60	56	46	58	106	134	26	35	28	1.0	2.0	0.25
Klebsiella oxytoca	0	1	7	55	155	80	19	22	5	12	13	14	9	4	11	11	0	1	0	1.0	2.0	0.125
Klebsiella pneumoniae	0	2	12	99	523	745	271	84	65	19	18	38	54	43	49	68	105	199	20	1.0	2.0	0.25
Klebsiella spp	0	5	21	86	103	73	34	13	16	11	1	1	2	1	0	1	1	0	0	1.0	2.0	0.125
Morganella morganii	0	8	27	35	24	18	12	8	6	2	1	10	4	2	2	0	0	1	0	1.0	2.0	ND
Proteus mirabilis	0	1	107	212	71	11	2	3	3	1	1	1	2	1	2	4	1	1	0	1.0	2.0	0.064
Proteus vulgaris	0	0	14	22	27	23	20	11	0	0	0	0	4	2	1	0	0	4	0	1.0	2.0	0.125
Salmonella spp	0	0	0	0	3	436	10648	1261	184	16	2	6	7	35	11	0	0	0	0	1.0	2.0	0.5
Serratia marcescens	0	0	0	0	0	3	51	35	34	44	12	19	33	25	24	9	1	48	0	1.0	2.0	1.0
Serratia spp	0	0	0	0	1	7	42	43	43	26	13	5	20	35	7	6	1	1	0	1.0	2.0	1.0

Catch the end of relevant wild types!

Catch both breakpoints!

Catch future breakpoints!

Catch relevant MICs!

Routine ATCC control strains may still not detect problems

Future phenotypic AST (6 – 8 h)

- Automated **disk diffusion testing**

- Fully automatic (provide inoculum):

- plate inoculation
- disk application
- incubation
- "variable" zone diameter reading: automatic reading at 6, 8, 12 and 18h.
- and zone diameter distribution databases to match.


- Database consisting of zone diameter distributions related to incubation time and with calibrated breakpoints.

- **Output:** Zone diameter + Clinical S, I or R + WT or NWT

Meropenem / Escherichia coli

EUCAST MIC Distribution - Reference Database 2012-04-01

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



MIC


Epidemiological cut-off: WT ≤ 0.125 mg/L

8005 observations (68 data sources)

Clinical breakpoints: S ≤ 2 mg/L, R > 8 mg/L

Meropenem / Escherichia coli
EUCAST zone diameter distribution - Reference database 2012-04-01
EUCAST disk diffusion method

Distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



Disk content: 10


Epidemiological cut-off: WT ≥ 26 mm (MIC ≤ 0.125 mg/L)

7027 observations (7 data sources)

Clinical breakpoints: S ≥ 26 mm, R < 16 mm (S ≤ 2 mg/L, R > 8 mg/L,)

Gentamicin / Enterococcus faecalis
EUCAST MIC Distribution - Reference Database 2012-03-28

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



MIC
Epidemiological cut-off: WT ≤ 32 mg/L

4783 observations (27 data sources)
Clinical breakpoints: Inappropriate

MIC testing and disk diffusion are hard to beat!

Disk /MIC testing

- Manual
- 16 – 20h (8h possible)
- Direct testing possible on pure cultures (blood, urine)
- Flexible and adaptable
- Little dependency
- Truly quantitative
- Standard lab equipment
- Cheap consumables
- Know-how in AST
- QC (regular ATCC)

Automated AST

- Semiautomated
- 8 – 16 – 20 h
- Direct testing possible on pure cultures (blood cultures)
- Non-flexible
- Dependency on manufacturer
- Blackbox/trapdoor results
- Expensive dedicated equipment
- Expensive consumables
- Know-how in machine
- QC (suppl MIC-range)

Rapid change

Flexibility

Flexibility

Flexibility

ESCMID Online © by author